Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 29, 2001

View Archived Issues

Fujisawa discusses SAR leading to potential new ED therapeutic

FR-149470: a new immunomodulator with improved profile compared to linomide

Dual AChE and 5-HT reuptake inhibitor RS-1439 may simultaneously treat AD and depression

Potential new cardiovascular therapeutic unveiled in Kyoto by Fujisawa

Fujisawa selects potent NPY Y5 antagonist for further testing

Tanabe Seiyaku improves pancreas selectivity of CCK-A receptor antagonists

Extensive coverage of ICN's second-generation ribavirin analogues at AASLD

Clinical program expanded for ALX1-11 in the treatment of osteoporosis

Biosearch Italia and Myriad collaborate on drug discovery

Encouraging results from phase IIa study of Esperion's ETC-588

Chiron grants nonexclusive HCV license to BMS

Initiation of phase I trial of orally active GnRH antagonist

Hepatoprotectant ME-3738 appears to act via an IL-6-dependent mechanism

MLN-4760 enters phase I trial for metabolic disease

Pharmacia claims new NOS inhibitors and their use in inflammation-related disorders

Preparation, activity and use of new factor Xa inhibitors claimed in recent patent

Thyroid receptor ligands synthesized by Pfizer particularly useful for obesity, diabetes

Notre Dame identifies new antimycobacterial agents

New macrocyclic antibiotics discovered at Microbial Chemistry Research Foundation

Discovery Partners and Takeda extend collaboration to include drug discovery

New Toray compounds potentiate cell proliferation

Wyeth-Ayerst licenses Ludwig Institute antibody for anticancer therapy

Potential analgesic alternative to morphine with low abuse potential -- HS-599

Start of expanded phase II clinical trial program for GD-0039 for metastatic renal cancer

Vascular inflammation programs planned under new Millennium-Xoma collaboration

Basiliximab: use in GI inflammatory disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...